Despite the clinical success of antibodies against immunomodulators such as PD‐L1/PD‐1 and CTLA4, only a small fraction of individuals have a lasting benefit, suggesting the urgency of an efficient cancer‐immunity cycle to iteratively proceed and expand, and thus generate anticancer immune responses.28, 29. Here, PDCD1 is linked to cancer.